Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | CASP3 | P42574 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.44 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | DAO | P14920 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7325746 | 0.82 | AOC3 (0.52) | AOC3RAB9ANPC1KDM4EMAPT | |
| SCHEMBL827599 | 0.78 | KDM4E (0.53) | AOC3RAB9ANPC1KDM4EMAPT | |
| SCHEMBL29950513 | 0.78 | AOC3 (0.54) | AOC3RAB9ANPC1KDM4EMAPT | |
| SCHEMBL10923717 | 0.78 | AOC3 (0.48) | AOC3RAB9ANPC1KDM4EMAPT | |
| SCHEMBL5850730 | 0.78 | FLT3 (0.48) | AOC3RAB9ANPC1KDM4EMAPT | |
| SCHEMBL2125162 | 0.78 | AOC3 (0.48) | AOC3RAB9ANPC1KDM4EMAPT | |
| SCHEMBL29614783 | 0.78 | KDM4E (0.53) | AOC3RAB9ANPC1KDM4EMAPT | |
| SCHEMBL3941037 | 0.77 | AOC3 (0.47) | AOC3RAB9ANPC1KDM4EMAPT | |
| Hydrochloric Acid SCHEMBL7218573 | 0.77 | KDM4E (0.51) | AOC3RAB9ANPC1KDM4EMAPT | |
| SCHEMBL4278358 | 0.75 | FLT3 (0.50) | AOC3RAB9ANPC1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090257975-A1 | Solid and Semi-Solid Polymeric Ionic Conjugates | PFIZER INC | 2009-10-15 | — | — | US | disclosed |
| WO-2006032957-A1 | IN VITRO PREDICTIVE METHOD | PFIZER PRODUCTS INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20060031021-A1 | In vitro predictive method | PFIZER INC | 2006-02-09 | — | — | US | disclosed |
| EP-1575616-A2 | NOVEL INJECTABLE DEPOT FORMULATIONS | Pfizer Products Inc. (US) | 2005-09-21 | — | — | EP | disclosed |
| EP-1562546-A1 | DEPOT FORMULATIONS OF ARYLHETEROCYCLIC ACTIVE AGENTS IN THE FORM OF A SUSPENSION | Pfizer Products Inc. (US) | 2005-08-17 | — | — | EP | disclosed |
| EP-1556086-A2 | SOLID AND SEMI-SOLID POLYMERIC IONIC CONJUGATES | Pfizer Products Inc. (US) | 2005-07-27 | — | — | EP | disclosed |
| EP-1556087-A2 | LIQUID CONJUGATES OF SOLID PHARMACEUTICALS | Pfizer Products Inc. (US) | 2005-07-27 | — | — | EP | disclosed |
| US-20040147532-A1 | Liquid conjugates of solid pharmaceuticals | PFIZER INC | 2004-07-29 | — | — | US | disclosed |
| US-20040146562-A1 | Depot formulations in the form of a suspension | PFIZER INC | 2004-07-29 | — | — | US | disclosed |
| US-20040142039-A1 | Solid and semi-solid polymeric ionic conjugates | PFIZER INC | 2004-07-22 | — | — | US | disclosed |
| US-20040138237-A1 | Novel injectable depot formulations | PFIZER INC | 2004-07-15 | — | — | US | disclosed |
| WO-2004039411-A2 | SOLID AND SEMI-SOLID POLYMERIC IONIC CONJUGATES | PFIZER PRODUCTS INC. (GB) | 2004-05-13 | — | — | WO | disclosed |
| WO-2004039410-A2 | LIQUID CONJUGATES OF SOLID PHARMACEUTICALS | PFIZER PRODUCTS INC. (US) | 2004-05-13 | — | — | WO | disclosed |
| WO-2004037289-A2 | NOVEL INJECTABLE DEPOT FORMULATIONS | PFIZER PRODUCTS INC. (US) | 2004-05-06 | — | — | WO | disclosed |
| WO-2004037224-A1 | DEPOT FORMULATIONS OF ARYLHETEROCYCLIC ACTIVE AGENTS IN THE FORM OF A SUSPENSION | PFIZER PRODUCTS INC. (US) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138237-A1 | Novel injectable depot formulations | NPY4R, GLP1R, GPR119 | AOC3 2790/4885RAB9A 2604/4885NPC1 422/4885 |
| US-20040146562-A1 | Depot formulations in the form of a suspension | LPXN, HAMP, GLP1R | AOC3 1121/4885RAB9A 1662/4885NPC1 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.